A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

In this comprehensive program centered on an in-person and online live CCO symposium at ASH 2021 experts discuss recent developments in the management of myelodysplastic syndromes. Review their insights in an on-demand webcast and downloadable slides from the symposium.

Share

Program Content

Activities

Lower-risk MDS Therapy
Therapeutic Approaches for the Treatment of Lower-Risk MDS and Anemia Management
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2021

Expires: December 09, 2022

Managing Higher-risk and RR MDS
Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDS
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2021

Expires: December 09, 2022

Immuno-oncology for MDS
Novel Therapeutic Strategies for MDS Focused on the Stroma and Immuno-oncology
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2021

Expires: December 09, 2022

<em>ExpressPoints</em>: Tx for MDS
ExpressPoints
A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 23, 2021

Expires: December 22, 2022

No activities added yet

Faculty

cover img faculity

Jacqueline S. Garcia, MD

Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts 

cover img faculity

Michael R. Savona, MD, FACP

Director of Leukemia Research
Senior Investigator, Hematologic Malignancies Research and Drug Development
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancers
Tennessee Oncology
Nashville, Tennessee

cover img faculity

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gamida Cell Ltd

Geron

Gilead Sciences, Inc.

Karyopharm Therapeutics Inc.

Takeda Pharma USA Inc Takeda Onc Co